Shares of Immunomedics Inc. (NASDAQ:IMMU) traded down 1.8% during trading on Monday . The company traded as low as $2.22 and last traded at $2.24, with a volume of 216,480 shares traded. The stock had previously closed at $2.28.

A number of analysts have recently commented on the company. Zacks Investment Research raised Immunomedics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 6th. Wells Fargo & Co. lowered shares of Immunomedics from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 21st. Finally, Jefferies Group restated a “buy” rating and issued a $5.00 price objective on shares of Immunomedics in a report on Monday, June 6th.

The firm has a 50-day moving average price of $2.87 and a 200 day moving average price of $2.77. The stock’s market capitalization is $215.21 million.

Immunomedics (NASDAQ:IMMU) last issued its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.02. Equities research analysts anticipate that Immunomedics Inc. will post ($0.57) earnings per share for the current year.

In other news, CEO Cynthia L. Goldenberg sold 371,990 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $3.03, for a total transaction of $1,127,129.70. Following the transaction, the chief executive officer now directly owns 650,396 shares of the company’s stock, valued at $1,970,699.88. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman David M. Goldenberg sold 110,322 shares of the firm’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $4.09, for a total transaction of $451,216.98. Following the transaction, the chairman now directly owns 2,602,063 shares in the company, valued at $10,642,437.67. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Immunomedics stock. Marshall Wace LLP acquired a new position in shares of Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned about 0.90% of Immunomedics at the end of the most recent quarter.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.